158 related articles for article (PubMed ID: 37688769)
1. A comprehensive survival and prognosis analysis of GPR55 expression in hepatocellular carcinoma.
Wang T; Xia K; Qiu T; Han S; Chen Z; Ma X; Zhang L; Zou J; Zhang Y; Yu B; Kong C; Guo J; Liu Y; Zhou J; Zheng S
Aging (Albany NY); 2023 Sep; 15(17):8930-8947. PubMed ID: 37688769
[TBL] [Abstract][Full Text] [Related]
2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
3. The Functional Roles of Immune Cells in Primary Liver Cancer.
Pham L; Kyritsi K; Zhou T; Ceci L; Baiocchi L; Kennedy L; Chakraborty S; Glaser S; Francis H; Alpini G; Sato K
Am J Pathol; 2022 Jun; 192(6):826-836. PubMed ID: 35337836
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies.
Argemi J; Ponz-Sarvise M; Sangro B
Adv Cancer Res; 2022; 156():367-413. PubMed ID: 35961706
[TBL] [Abstract][Full Text] [Related]
5. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
Ruff SM; Shannon AH; Pawlik TM
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
[TBL] [Abstract][Full Text] [Related]
6. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
7. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
[No Abstract] [Full Text] [Related]
8. Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
Chen LX; Zou SJ; Li D; Zhou JY; Cheng ZT; Zhao J; Zhu YL; Kuang D; Zhu XH
World J Gastroenterol; 2020 Dec; 26(48):7664-7678. PubMed ID: 33505143
[TBL] [Abstract][Full Text] [Related]
9. Comparison of hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC) with each other based on microarray dataset.
Wang L
Tumour Biol; 2013 Jun; 34(3):1679-84. PubMed ID: 23532688
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
11. Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers - how to push the gas after having released the brake.
Rakké YS; Buschow SI; IJzermans JNM; Sprengers D
Front Immunol; 2024; 15():1357333. PubMed ID: 38440738
[TBL] [Abstract][Full Text] [Related]
12. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
[TBL] [Abstract][Full Text] [Related]
13. Tumor Microenvironment: Necroptosis Switches the Subtype of Liver Cancer While Necrosis Promotes Tumor Recurrence and Progression.
Özdemir BH
Exp Clin Transplant; 2023 Apr; 21(4):291-298. PubMed ID: 35297332
[TBL] [Abstract][Full Text] [Related]
14. Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor.
Huang L; Ramirez JC; Frampton GA; Golden LE; Quinn MA; Pae HY; Horvat D; Liang LJ; DeMorrow S
Lab Invest; 2011 Jul; 91(7):1007-17. PubMed ID: 21464819
[TBL] [Abstract][Full Text] [Related]
15. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
16. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
17. Targeting YAP1 to improve the efficacy of immune checkpoint inhibitors in liver cancer: mechanism and strategy.
Gao Y; Gong Y; Lu J; Hao H; Shi X
Front Immunol; 2024; 15():1377722. PubMed ID: 38550587
[TBL] [Abstract][Full Text] [Related]
18. Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis.
Xue TC; Zhang BH; Ye SL; Ren ZG
Tumour Biol; 2015 Aug; 36(8):5891-9. PubMed ID: 25712376
[TBL] [Abstract][Full Text] [Related]
19. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
20. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling.
Rosenberg N; Van Haele M; Lanton T; Brashi N; Bromberg Z; Adler H; Giladi H; Peled A; Goldenberg DS; Axelrod JH; Simerzin A; Chai C; Paldor M; Markezana A; Yaish D; Shemulian Z; Gross D; Barnoy S; Gefen M; Amran O; Claerhout S; Fernández-Vaquero M; García-Beccaria M; Heide D; Shoshkes-Carmel M; Schmidt Arras D; Elgavish S; Nevo Y; Benyamini H; Tirnitz-Parker JEE; Sanchez A; Herrera B; Safadi R; Kaestner KH; Rose-John S; Roskams T; Heikenwalder M; Galun E
J Hepatol; 2022 Dec; 77(6):1631-1641. PubMed ID: 35988690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
